On November 25, 2025, during the 15th Guangdong-Singapore Cooperation Council Meeting, Guangzhou Laien Biological Medicine Co., Ltd. (hereinafter referred to as "Laien Bio") and Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences signed a cooperation framework agreement under the joint witness of Meng Fanli, Governor of Guangdong Province, and Ong Ye Kung, Singapore's Minister for Health. Both parties will jointly develop in vivo universal cell therapy technology for cancer treatment. This marks the first time that the two parties have reached an in-depth cooperation in this field, representing a further expansion of Laien Bio into the in vivo cell therapy sector, and an important milestone in the company’s development through strong external collaborations.
iIn Vivo Cell Therapy as a Frontier Field of Precision Medicine: Its R&D and Translation Depend on Multidisciplinary Collaboration, with Each Step Requiring Efficient Communication and Cooperation Among Cross-Disciplinary Teams. The Collaborative Project Will Focus on the Joint Development of Universal In Vivo Cell Treatment Technologies., Accelerating the Clinical Translation of in vivo Therapies in Tumor TreatmentDifferent from the traditional in vitro preparation model of cellular therapy, the in vivo strategy offers advantages such as ready-to-use availability, low cost, and high accessibility. By directly guiding and activating immune cells within the patient’s body, this type of "off-the-shelf" cellular therapy could eliminate the need for individualized, case-by-case preparation, achieving an immediate treatment effect and thereby benefiting a broader patient population.It is reported that in vivo cell therapy has become a globally recognized new-generation cell and gene therapy development strategy, attracting investments and efforts from multiple international pharmaceutical companies. In this collaboration, Guangzhou Laien Biological Medicine Co., Ltd. will fully leverageExisting RNA technology andAdvantages of the TCR-T Technology Platform, andCAS DeepCombined with the profound scientific research strength of Zhong Advanced Institute, aiming to overcome the key issues of universal cell therapy in vivo.DeliveryTechnical challenges, driving the new generation of cell therapyTechnologyBreakthrough andClinicalApplication.Laien Bio is a company from the Agency for Science, Technology and Research (A*STAR) in Singapore.（A*STAR）Clinical-stage biotechnology company incubated. Core product is mRNA-encoded targeting of hepatitis B virus.（HBV）TCR-T Cell Therapy for the Treatment of HBV-Related Diseases. FDA approved itsConduct International Multicenter Phase II Clinical Trial for Liver Cancer`, the first such therapy approved by the FDA`，AndGranted FDA Fast Track and Orphan Drug Designation. Recently, the FDAAgainApproval for its expanded treatment of chronic hepatitis B。The company relies on AI-driven target discoveryAndRNATechnologyThe platform is actively expanding its pipeline for treating various solid tumors and infectious diseases, focusing on developing in vivo TCR-T universal cell therapies.Strive for a significant increaseReduce Costs, and thenRaiseHighPatient accessibility.Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, as a national-level scientific research institution,In advanced therapeutic drugs, CGT, and bioactive materials, etc.The biopharmaceutical field boasts strong R&D capabilities. This collaboration between the two parties represents the integration of industrial and scientific research strengths, with Shenzhen Advanced Institute's cutting-edge fundamental research capabilities complementing Guangzhou Laien Biological Medicine Co., Ltd.'s clinical development experience.On the significance of the China-Singapore cooperation platform,Linztao Cai, Director of Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences"This collaboration between China and Singapore in the biopharmaceutical field reflects complementary strengths. It not only connects research capabilities with clinical translation but also enhances the efficiency of the China-Singapore cooperation platform in cross-border collaboration, accelerating the transformation of fundamental research into clinical value. This effort supports the development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area and is expected to serve as a model for global cross-border scientific research collaboration."Dr. Peng Xiaoming, CEO of Guangzhou Laien Biological Medicine Co., Ltd.It was pointed out that: "Guangzhou Laien Biological Medicine Co., Ltd. carries the genes of Sino-Singapore innovation collaboration, and this time with...Chinese Academy of SciencesThe cooperation of Shenzhen Advanced Institute is a part of the China-Singapore cooperation platform.AgainAn upgrade — We will closely integrate Singapore's technical accumulation in the field of cell therapy with China's scientific research strength and clinical transformation system, forming a full-chain collaboration from scientific research to clinical application. In the future, we will also promote talent and technology sharing between the two countries, contributing more Sino-Singaporean wisdom to the global development of cell therapy."Looking ahead, the two parties will advance the research and development plan according to the agreement, conducting comprehensive collaboration from fundamental mechanism research, technology platform construction to preclinical studies. This cooperation is expected to accelerate...in vivoDevelopment of universal cell therapy technology to promote the early clinical application of achievements, which is also an important strategic expansion in Laien Biological's cell therapy portfolio. In the future, the company will continue to deepen collaborative innovation with top research institutions to consolidate its leading position in the field of universal TCR-T cell therapy.
WeChat ID｜Laien Bio
Official Website｜https://www.liontcr.com/
